IL6 and colitis: reported that luteolin blocked NF-κB activation by inhibiting IKKα/β phosphorylation, thereby reducing pro-inflammatory cytokines (IL-6, TNF-α) in LPS-stimulated macrophages and ameliorating DSS-induced colitis (65).